[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"logopenic-progressive-aphasia-lpa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:logopenic-progressive-aphasia-lpa":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100265889","molecular-and-structural-imaging-in-alzheimers-disease-a-longitudinal-study-100265889",false,"NCT02740634","Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study","Inclusion Criteria:\n\n* Over the age of 21\n* Must have an informant who will be able to provide independent evaluation of functioning\n* English is primary language\n* All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).\n* All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language\n* All subjects with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain\n\nExclusion Criteria:\n\n* If you have had a stroke or tumor that could explain your symptoms\n* Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study\n* Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded\n* Subjects will be excluded if they have poor vision (20\u002F400)\n* Women that are pregnant or post-partum and breast-feeding will be excluded\n* Subjects will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome\n* Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy)","ALL","21 Years","80 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.",[26,27,28,29,30,31,32,33],"Atypical Alzheimer's Disease","Logopenic Progressive Aphasia (LPA)","Posterior Cortical Atrophy (PCA)","Alzheimer Disease","Alzheimer Disease, Early Onset","Amnestic Disorder","Amnestic Symptoms","Amnestic Mild Cognitive Disorder",[35,36,37,38],"PCA","LPA","AD","Amnestic AD","RECRUITING","2026-07-16",{"date":42,"type":43},"2026-07-17","ACTUAL",{"date":45,"type":4},"2016-05",{"date":47,"type":20},"2027-03",{"name":49,"class":50},"Mayo Clinic","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":15,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100612951","remotely-supervised-neuromodulation-in-ppa-100612951","NCT07260253","Remotely-supervised Neuromodulation in PPA","Investigating the Benefits of Remotely-Supervised Neuromodulation In Primary Progressive Aphasia","Inclusion Criteria:\n\n* Meets diagnostic criteria for primary progressive aphasia (PPA)\n* Meets diagnostic criteria for logopenic variant PPA\n* Attains score of 15 or higher on the Mini-Mental State Examination\n* Has adequate hearing and vision (with hearing or vision aids, if needed)\n* Is able to travel to research site and undergo MRI brain scan\n* Has access to high speed internet and basic experience using a computer and the internet\n* Is a fluent speaker of English\n* Has a study partner who can co-enroll in the study, attend pre-treatment training at the research site, and be present for teleconference meetings, as needed\n\nExclusion Criteria:\n\n* Speech and language deficits better accounted for by another neurological disorder\n* Does not meet diagnostic criteria for logopenic variant PPA\n* Scores less than 15 on the Mini-Mental State Examination\n* Does not have a study partner who can co-enroll in the study\n* Has contraindications for tDCS or MRI scan (History of seizures, head injury, craniotomy, skull surgery or fracture; History of severe or frequent migraines; Metallic implant in head or any metal in head; Pacemaker or cardioverter-defibrillator or any other stimulator; Chronic skin problems; Pregnancy)\n* Has a history of stroke, epilepsy, or significant brain injury","40 Years",{"count":61,"type":20},80,[23],"The goal of this clinical trial is to learn whether home-based brain stimulation combined with virtual speech-language therapy can improve communication abilities in adults with logopenic variant primary progressive aphasia (lvPPA), a language disorder most often caused by Alzheimer's disease.\n\nThe main questions the study aims to answer are:\n\n* Is combining remotely supervised transcranial direct current stimulation (tDCS) with virtual speech-language therapy feasible and acceptable for people with lvPPA?\n* Does this combined treatment lead to improvements in communication compared to speech-language therapy with sham (placebo) stimulation?\n* Do individual brain characteristics help predict who benefits most from this treatment?\n\nResearchers will compare participants who receive active tDCS plus virtual speech-language therapy to participants who receive sham (placebo) tDCS plus virtual speech-language therapy to see if active brain stimulation enhances communication outcomes.\n\nParticipants will:\n\n* Complete speech-language therapy sessions delivered by video visit.\n* Receive either active or sham tDCS that is remotely supervised and completed at home.\n* Complete language and cognitive testing before and after treatment.\n* Undergo brain imaging and other assessments to help understand treatment response.",[65,66,67,27,68,69],"Primary Progressive Aphasia(PPA)","Progressive Aphasia","Progressive Aphasia in Alzheimer's Disease","Logopenic Variant Primary Progressive Aphasia","Logopenic Variant of Primary Progressive Aphasia (LPA)",[71,72,73,74,75,76,77,78,79,80,81,82],"lvPPA","PPA","logopenic variant PPA","transcranial direct-current stimulation","tDCS","neuromodulation","speech therapy","speech-language pathology","logopenic","teletherapy","remote","virtual","2026-06-24",{"date":85,"type":43},"2026-06-29",{"date":87,"type":43},"2026-04-15",{"date":89,"type":20},"2029-08",{"name":91,"class":50},"Maya Henry",2,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":59,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":113,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":51},"100609830","intervention-for-communication-quality-of-life-in-primary-progressive-aphasia-100609830","NCT07219680","Intervention for Communication Quality of Life in Primary Progressive Aphasia","Intervention to Promote Communication Quality of Life for Persons With Language-Led Dementia and Their Partners: A Randomized Pilot Trial","Multi-PA","Inclusion Criteria for Persons with PPA:\n\n* A PPA (Gorno-Tempini et al., 2011) or \"PPA-plus\" (Mesulam et al., 2001) diagnosis\n* MMSE score of 15 or higher and must be able to produce single monosyllabic words intelligibly\n* Must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)\n* Hearing and vision adequate for participation in teleconference meetings\n* Must have a study partner available (someone who will commit to attending teleconference sessions, as needed, during assessment and treatment phases)\n\nInclusion criteria for Care Partners:\n\n* Partners must express willingness to attend and participate in assessment and treatment sessions, including those targeting dyadic communication goals\n* Partners must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)\n* Partner's hearing and vision should be adequate for participation in teleconference meetings\n\nThe participant and\u002For study partner must have basic experience using a computer.\n\nExclusion criteria for persons with PPA:\n\n* Other central nervous system or medical diagnosis that can account for symptoms\n* Psychiatric diagnosis that can account for symptoms",{"count":102,"type":20},30,[23],"The goal of this clinical trial is to learn whether a personalized, multi-component, virtual speech language treatment program can improve communication and quality of life for adults with primary progressive aphasia (PPA) and their primary communication partners. The study will enroll participants who speak English and\u002For Spanish.\n\nThe main questions the study aims to answer are:\n\n* Is the telerehabilitation program feasible and acceptable for people with PPA and their study partners?\n* Do participants with PPA and study partners find treatment beneficial?\n* What patterns of treatment response are seen in participants?\n* Which outcome measures are most useful for evaluating changes in communication and quality of life?\n\nResearchers will compare participants who receive intervention immediately to participants assigned to a waitlist control group (who will receive treatment after a delay) to see whether participation in the treatment program is associated with improvements in communication and quality of life.\n\nParticipants will:\n\n* Take part in speech language therapy sessions delivered by video visit that combine restorative, compensatory, and partner-focused communication strategies. Treatment may take place after a waiting period.\n* Receive education and communication training together with their partner.\n* Complete speech, language, and cognitive assessments.\n* Complete questionnaires about communication abilities, daily functioning, and quality of life.",[65,106,27,107,66,108,109,68,69,110,111,112],"Semantic Dementia","Nonfluent Aphasia, Progressive","Semantic Variant Primary Progressive Aphasia (svPPA)","Semantic Aphasia","Logopenic Progressive Aphasia","Nonfluent Variant Primary Progressive Aphasia (nfvPPA)","Nonfluent Progressive Aphasia",[78,114,79,115,116,117,80,81,118,119,120,121,122,123,124,125,126],"neurodegenerative disease","nonfluent","semantic","script training","multimodal communication training","partner training","augmentative and alternative communication","AAC","Communication Book","bilingual","Spanish","Hispanic","Latino",{"date":128,"type":43},"2026-04-21",{"date":130,"type":43},"2026-04-01",{"date":132,"type":20},"2027-08",{"name":91,"class":50}]